Lava Therapeutics Nv Reports Results For The Quarter Ended In June: Earnings Summary

LAVA Therapeutics NV

13/09/2022 21:40

* LAVA Therapeutics NV  LVTX.OQ  reported a quarterly
adjusted
loss of 31 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 59 cents per share.
    * Revenue was €468.00 thousand​; analysts expected €333.33
thousand. 
    * LAVA Therapeutics NV's reported EPS for the quarter was a
loss
of 31 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * LAVA Therapeutics NV shares had fallen by 14.9% this
quarter and
lost 54.4% so far this year.
    * The company reported a quarterly loss of €14.58 million.
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $23.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data September
13 at 08:40 p.m.  ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.59          -0.31          Beat
 Mar. 31 2022      -0.81          -0.41          Beat
 Dec. 31 2021      -0.36          -0.38          Missed
 Sep. 30 2021      -0.27          -0.23          Beat